Mike Thompson to become Chief Executive of the Association of the British Pharmaceutical Industry

He takes up the position on 1 March and Acting CEO Alison Clough will step down

Mike Thompson has been appointed as Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), effective 1 March 2016.

Thompson has worked across multiple sectors including pharmaceuticals, food, drinks, toiletries and Government agencies.

At the end of 2015, he left GlaxoSmithKline after 20 years with the company, most recently as Senior Vice President of Global Commercial Strategy and Platforms.

Prior to this, Thompson spent seven years as GSK's Commercial Strategy Head for Europe and before that, ten years in the UK Operating Company in a variety of senior sales and marketing roles.

Before GSK, Thompson worked in Unilever's food and toiletries divisions, joining as a Commercial Trainee and latterly becoming a Marketing Director in the UK.

Alison Clough, who has spent the last 12 months as Acting CEO at the ABPI, will step aside.

You may also like

Drug Delivery

ABPI: “New antibiotics key against resistance infections”

In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections
Regulatory

ABPI: Tackling vaccine hesitancy should be a priority

The Association of the British Pharmaceutical Industry responds to the UK's commitment to improving declining vaccination rates
Regulatory

New medicine safety initiative goes live across the UK and Europe

The ABPI raises concerns about the safety of the UK's medicines in a ‘no deal’ Brexit
Research & Development

ABPI urges the UK to address the skills shortage in STEM

Highly skilled scientific roles could move elsewhere if the situation is not addressed as a matter of urgency
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

NHS, Pharma and Biotech industries call on Government to protect patients in future UK-EU relationship

A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU
Research & Development

Scotland’s manufacturing exports worth £462 million

The Scottish pharmaceutical industry is ‘booming’ and is now the second biggest spender on R&D, a new report has revealed
Subscribe now